Review Article

Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States

Table 2

NCCN guidelines (version 2.2013): criteria for further genetic risk evaluation for breast/ovarian cancer.

An affected individual with one or more of the followingAn unaffected individual with a family history of one or more of the following

A known mutation in a breast cancer susceptibility gene within the familyA known mutation in a breast cancer susceptibility gene within the family
Early age of onset (≤50 years)≥2 breast primaries in a single individual
Triple negative (ER-, PR-, HER2-) breast cancer≥2 individuals with breast primaries on the same side of the family
Two breast cancer primaries in a single individual
Breast cancer at any age and 1 of the following:≥1 ovarian cancer primary from the same side of the family
 ≥1 close blood relative with breast cancer <50 y
 ≥1 close blood relative with epithelial ovarian cancer (any age)First- or second-degree relative with breast cancer ≤45 y
 ≥2 close blood relatives with breast cancer and/or pancreatic
 cancer at any age
 From a population at increased risk
≥1 family member on same side of family with a combination of breast cancer and ≥1 of following: pancreatic cancer, aggressive prostate cancer, sarcoma, adrenocortical carcinoma, brain tumors, endometrial cancer, leukemia/lymphoma, thyroid cancer, dermatologic manifestations and/or macrocephaly, hamartomatous polyps of GI tract, and diffuse gastric cancer≥1 family member on same side of family with a combination of breast cancer and ≥1 of following: pancreatic cancer, aggressive prostate cancer, sarcoma, adrenocortical carcinoma, brain tumors, endometrial cancer, leukemia/lymphoma, thyroid cancer, dermatologic manifestations and/or macrocephaly, hamartomatous polyps of GI tract, and diffuse gastric cancer
Ovarian cancerMale breast cancer
Male breast cancer